PMC:7311890 / 21616-21929 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T145","span":{"begin":43,"end":49},"obj":"Body_part"},{"id":"T146","span":{"begin":107,"end":128},"obj":"Body_part"},{"id":"T147","span":{"begin":130,"end":133},"obj":"Body_part"},{"id":"T148","span":{"begin":280,"end":282},"obj":"Body_part"}],"attributes":[{"id":"A145","pred":"fma_id","subj":"T145","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A146","pred":"fma_id","subj":"T146","obj":"http://purl.org/sig/ont/fma/fma85436"},{"id":"A147","pred":"fma_id","subj":"T147","obj":"http://purl.org/sig/ont/fma/fma85436"},{"id":"A148","pred":"fma_id","subj":"T148","obj":"http://purl.org/sig/ont/fma/fma66595"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T108","span":{"begin":295,"end":303},"obj":"Disease"}],"attributes":[{"id":"A108","pred":"mondo_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T206","span":{"begin":43,"end":49},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T207","span":{"begin":280,"end":282},"obj":"http://purl.obolibrary.org/obo/CLO_0001562"},{"id":"T208","span":{"begin":283,"end":291},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T243","span":{"begin":50,"end":70},"obj":"Chemical"},{"id":"T244","span":{"begin":81,"end":99},"obj":"Chemical"},{"id":"T245","span":{"begin":94,"end":99},"obj":"Chemical"},{"id":"T246","span":{"begin":101,"end":104},"obj":"Chemical"},{"id":"T247","span":{"begin":107,"end":128},"obj":"Chemical"},{"id":"T248","span":{"begin":130,"end":133},"obj":"Chemical"},{"id":"T250","span":{"begin":196,"end":213},"obj":"Chemical"}],"attributes":[{"id":"A243","pred":"chebi_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/CHEBI_37739"},{"id":"A244","pred":"chebi_id","subj":"T244","obj":"http://purl.obolibrary.org/obo/CHEBI_16337"},{"id":"A245","pred":"chebi_id","subj":"T245","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A246","pred":"chebi_id","subj":"T246","obj":"http://purl.obolibrary.org/obo/CHEBI_16337"},{"id":"A247","pred":"chebi_id","subj":"T247","obj":"http://purl.obolibrary.org/obo/CHEBI_28874"},{"id":"A248","pred":"chebi_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/CHEBI_53232"},{"id":"A249","pred":"chebi_id","subj":"T248","obj":"http://purl.obolibrary.org/obo/CHEBI_28874"},{"id":"A250","pred":"chebi_id","subj":"T250","obj":"http://purl.obolibrary.org/obo/CHEBI_16961"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"640","span":{"begin":266,"end":282},"obj":"Gene"},{"id":"648","span":{"begin":304,"end":312},"obj":"Species"},{"id":"652","span":{"begin":50,"end":70},"obj":"Chemical"},{"id":"653","span":{"begin":81,"end":99},"obj":"Chemical"},{"id":"654","span":{"begin":101,"end":104},"obj":"Chemical"},{"id":"655","span":{"begin":107,"end":128},"obj":"Chemical"},{"id":"656","span":{"begin":130,"end":133},"obj":"Chemical"},{"id":"657","span":{"begin":196,"end":213},"obj":"Chemical"},{"id":"658","span":{"begin":237,"end":241},"obj":"Chemical"},{"id":"683","span":{"begin":295,"end":303},"obj":"Disease"}],"attributes":[{"id":"A640","pred":"tao:has_database_id","subj":"640","obj":"Gene:5319"},{"id":"A648","pred":"tao:has_database_id","subj":"648","obj":"Tax:9606"},{"id":"A652","pred":"tao:has_database_id","subj":"652","obj":"MESH:D020404"},{"id":"A653","pred":"tao:has_database_id","subj":"653","obj":"MESH:D010712"},{"id":"A654","pred":"tao:has_database_id","subj":"654","obj":"MESH:D010712"},{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"MESH:D010716"},{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"MESH:D010716"},{"id":"A657","pred":"tao:has_database_id","subj":"657","obj":"MESH:D008246"},{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T33","span":{"begin":266,"end":291},"obj":"http://purl.obolibrary.org/obo/GO_0032431"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T148","span":{"begin":0,"end":313},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T455","span":{"begin":43,"end":49},"obj":"UBERON:0001969"},{"id":"T456","span":{"begin":50,"end":70},"obj":"CHEBI:37739;CHEBI:37739"},{"id":"T457","span":{"begin":81,"end":99},"obj":"CHEBI:16337;CHEBI:16337"},{"id":"T458","span":{"begin":101,"end":104},"obj":"CHEBI:18303;CHEBI:18303"},{"id":"T459","span":{"begin":107,"end":128},"obj":"CHEBI:28874;CHEBI:28874"},{"id":"T460","span":{"begin":196,"end":213},"obj":"CHEBI:16247;CHEBI:16247"},{"id":"T461","span":{"begin":221,"end":225},"obj":"CHEBI:16412;CHEBI:16412"},{"id":"T462","span":{"begin":295,"end":303},"obj":"SP_7"},{"id":"T89554","span":{"begin":36,"end":43},"obj":"MOP:0000568"},{"id":"T51487","span":{"begin":52,"end":61},"obj":"CHEBI:16990;CHEBI:16990"},{"id":"T18836","span":{"begin":79,"end":90},"obj":"GO:0045333"},{"id":"T43909","span":{"begin":140,"end":149},"obj":"CHEBI:16990;CHEBI:16990"},{"id":"T77168","span":{"begin":247,"end":255},"obj":"SP_7"},{"id":"T75518","span":{"begin":284,"end":292},"obj":"MOP:0000568"}],"text":"We observed reductions in major classes of plasma glycerophospholipids including phosphatidic acids (PAs), phosphatidylinositols (PIs), and PCs, with accompanying increases in their corresponding lysophospholipids (i.e., LPAs, LPIs, and LPCs) that indicate enhanced phospholipase A2 activity in COVID-19 patients."}